Skip to main content

Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer


Searching for OpenAIRE data...


A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy

Author(s): Arthur Jochems, Issam El-Naqa, Marc Kessler, Charles S. Mayo, Shruti Jolly, Martha Matuszak, Corinne Faivre-Finn, Gareth Price, Lois Holloway, Shalini Vinod, Matthew Field, Mohamed Samir Barakat, David Thwaites, Dirk de Ruysscher, Andre Dekker, Philippe Lambin
Published in: Acta Oncologica, Issue 57/2, 2017, Page(s) 226-230, ISSN 0284-186X
DOI: 10.1080/0284186X.2017.1385842

How Advances in Imaging Will Affect Precision Radiation Oncology

Author(s): David A. Jaffray, Shiva Das, Paula M. Jacobs, Robert Jeraj, Philippe Lambin
Published in: International Journal of Radiation Oncology*Biology*Physics, Issue 101/2, 2018, Page(s) 292-298, ISSN 0360-3016
DOI: 10.1016/j.ijrobp.2018.01.047

The posterior cerebellum, a new organ at risk?

Author(s): Daniëlle B.P. Eekers, Lieke in 't Ven, Sabine Deprez, Linda Jacobi, Erik Roelofs, Ann Hoeben, Philippe Lambin, Dirk de Ruysscher, Esther G.C. Troost
Published in: Clinical and Translational Radiation Oncology, Issue 8, 2018, Page(s) 22-26, ISSN 2405-6308
DOI: 10.1016/j.ctro.2017.11.010

Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review

Author(s): Daniëlle B.P. Eekers, Esther N. Pijnappel, Olaf E.M.G. Schijns, Albert Colon, Ann Hoeben, Jaap D. Zindler, Alida A. Postma, Aswin L. Hoffmann, Philippe Lambin, Esther G.C. Troost
Published in: Seizure, Issue 55, 2018, Page(s) 83-92, ISSN 1059-1311
DOI: 10.1016/j.seizure.2018.01.009

Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription

Author(s): Ana Ureba, Emely Lindblom, Alexandru Dasu, Johan Uhrdin, Aniek J. G. Even, Wouter van Elmpt, Philippe Lambin, Peter Wersäll, Iuliana Toma-Dasu
Published in: Acta Oncologica, Issue 57/4, 2017, Page(s) 485-490, ISSN 0284-186X
DOI: 10.1080/0284186X.2017.1400177

Towards a Clinical Decision Support System for External Beam Radiation Oncology Prostate Cancer Patients: Proton vs. Photon Radiotherapy? A Radiobiological Study of Robustness and Stability

Author(s): Seán Walsh, Erik Roelofs, Peter Kuess, Yvonka van Wijk, Ben Vanneste, Andre Dekker, Philippe Lambin, Bleddyn Jones, Dietmar Georg, Frank Verhaegen
Published in: Cancers, Issue 10/2, 2018, Page(s) 55, ISSN 2072-6694
DOI: 10.3390/cancers10020055

Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer

Author(s): Davide Cusumano, Nicola Dinapoli, Luca Boldrini, Giuditta Chiloiro, Roberto Gatta, Carlotta Masciocchi, Jacopo Lenkowicz, Calogero Casà, Andrea Damiani, Luigi Azario, Johan Van Soest, Andre Dekker, Philippe Lambin, Marco De Spirito, Vincenzo Valentini
Published in: La radiologia medica, Issue 123/4, 2018, Page(s) 286-295, ISSN 0033-8362
DOI: 10.1007/s11547-017-0838-3

Multi-Scale Modeling and Oxygen Impact on Tumor Temporal Evolution: Application on Rectal Cancer During Radiotherapy

Author(s): Sena Apeke, Laurent Gaubert, Nicolas Boussion, Philippe Lambin, Dimitris Visvikis, Vincent Rodin, Pascal Redou
Published in: IEEE Transactions on Medical Imaging, Issue 37/4, 2018, Page(s) 871-880, ISSN 0278-0062
DOI: 10.1109/TMI.2017.2771379

Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study

Author(s): Ralph TH Leijenaar, Marta Bogowicz, Arthur Jochems, Frank JP Hoebers, Frederik WR Wesseling, Sophie H Huang, Biu Chan, John N Waldron, Brian O'Sullivan, Derek Rietveld, C Rene Leemans, Ruud H Brakenhoff, Oliver Riesterer, Stephanie Tanadini-Lang, Matthias Guckenberger, Kristian Ikenberg, Philippe Lambin
Published in: The British Journal of Radiology, 2018, Page(s) 20170498, ISSN 0007-1285
DOI: 10.1259/bjr.20170498

18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study

Author(s): Sara Carvalho, Ralph T. H. Leijenaar, Esther G. C. Troost, Janna E. van Timmeren, Cary Oberije, Wouter van Elmpt, Lioe-Fee de Geus-Oei, Johan Bussink, Philippe Lambin
Published in: PLOS ONE, Issue 13/3, 2018, Page(s) e0192859, ISSN 1932-6203
DOI: 10.1371/journal.pone.0192859

Results and adverse events of personalized peptide receptor radionuclide therapy with <sup>90</sup>Yttrium and <sup>177</sup>Lutetium in 1048 patients with neuroendocrine neoplasms

Author(s): Richard P. Baum, Harshad R. Kulkarni, Aviral Singh, Daniel Kaemmerer, Dirk Mueller, Vikas Prasad, Merten Hommann, Franz C. Robiller, Karin Niepsch, Holger Franz, Arthur Jochems, Philippe Lambin, Dieter Hörsch
Published in: Oncotarget, Issue 9/24, 2018, ISSN 1949-2553
DOI: 10.18632/oncotarget.24524

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

Author(s): Relinde I. Y. Lieverse, Damiënne Marcus, Alexander M. A. Wiel, Evert J. Van Limbergen, Jan Theys, Ala Yaromina, Philippe Lambin, Ludwig J. Dubois
Published in: Molecular Oncology, 2020, ISSN 1574-7891
DOI: 10.1002/1878-0261.12705

Will immunotherapy really change radiotherapy?

Author(s): Lambin, P., Lieverse, R., Baumann, M., Ebert, N.
Published in: The Lancet Oncology, Issue 20/12, 2019, Page(s) 1642-1644, ISSN 1470-2045
DOI: 10.1016/s1470-2045(19)30682-5

Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy

Author(s): Philippe Lambin, Relinde I.Y. Lieverse, Franziska Eckert, Damiënne Marcus, Cary Oberije, Alexander M.A. van der Wiel, Chandan Guha, Ludwig J. Dubois, Joseph O. Deasy
Published in: Seminars in Radiation Oncology, Issue 30/2, 2020, Page(s) 187-193, ISSN 1053-4296
DOI: 10.1016/j.semradonc.2019.12.003

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Author(s): Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina,
Published in: BMC Cancer, Issue 20/1, 2020, ISSN 1471-2407
DOI: 10.1186/s12885-020-07055-1